TECHNE CORPORATION ANNOUNCES LITIGATION SETTLEMENT Minneapolis/May 30, 2002/-- Techne Corporation announced today that it has settled its pending litigation with Amgen, Inc. with a cash payment of $17.5 million. In connection with the settlement, Techne will take a charge to earnings in the current quarter for the amount of the settlement. The after-tax amount of the charge will be approximately $11.4 million or $0.27 per share. The settlement will have no effect on future results of Techne other than the loss of interest income on the cash being paid. Techne expects to have a fully productive relationship with Amgen. Future operations and sales of Techne will not be affected adversely in any way. On an operating basis, excluding effects of the Amgen settlement, Techne continues to expect that it will achieve record results in the fourth quarter and fiscal year ending June 30. Techne also expects that as of June 30, after paying the Amgen settlement, it will have a cash plus short term investments balance of approximately $95 million. Statements in this release and elsewhere which look forward in time, including expectations of results for the fourth quarter and fiscal year, involve risks and uncertainties which may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the outcome of litigation involving the Company, the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research into cytokines by the Company's customers, the impact of the growing number of producers of cytokine research products and related price competition, the retention of hematology OEM and proficiency survey business, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. * * * * * * * * * * * * * * Techne Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products and R&D Europe is a distributor of biotechnology products. * * * * * * * * * * * * * * Contact: Timothy M. Heaney, Vice President and General Counsel (612)362-8821